Quick answer: most do, but the differences between drugs are large — larger than for any other medication class covered on this site. Olanzapine and clozapine sit at one end, aripiprazole, lurasidone and ziprasidone at the other, and the gap between them runs to several kilograms.
Before anything else: antipsychotics treat conditions where stopping carries severe consequences, including relapse and hospitalisation. Nothing on this page is a reason to stop, skip or reduce a dose. It is written so you can have a better-informed conversation with your psychiatrist, because weight is a legitimate thing to weigh alongside how well a medication controls symptoms — and because there are often real alternatives.
Why Every Source Gives You a Different Number
This is the single most confusing thing about the topic, and it explains why the figure you were quoted may bear no relation to your experience.
A large network meta-analysis of acute trials — 100 studies, median duration six weeks — found the highest weight gain with clozapine at about 3 kg above placebo, and no evidence of weight gain at all with haloperidol, aripiprazole, ziprasidone, lurasidone, amisulpride and several others.
A separate network meta-analysis of mid- to long-term trials produced substantially bigger numbers for the same drugs. And a meta-analysis of olanzapine in people experiencing first-episode psychosis found a mean gain of around 7.5 kg.
Same medicines, very different figures. Two things drive the gap:
- Duration. Six weeks captures the beginning of a process that continues for months.
- Whether the person has taken an antipsychotic before. People starting their first antipsychotic gain considerably more than people switching from one to another. Most trials are switch studies, so they systematically understate what a first-time patient should expect.
The practical consequence: if you are starting an antipsychotic for the first time, the six-week trial figures are the wrong ones to plan around. This matters most for young people in a first episode, who are both the most vulnerable to the metabolic effects and the most likely to be on the medication for a long time.
Drug by Drug, Over the Longer Term
These figures come from a network meta-analysis of mid- to long-term randomised trials, expressed as mean weight gain in excess of placebo. They are averages across groups, not predictions for an individual.
| Band | Drugs |
|---|---|
| More than 2 kg above placebo | Pimozide (6.16), chlorpromazine (5.13), clozapine (4.21), zotepine (3.87), olanzapine (3.82 oral / 3.60 long-acting), sertindole (2.30) |
| 1 to 2 kg | Risperidone (2.00 long-acting / 1.87 oral), brexpiprazole (1.91), paliperidone (1.73 oral / 1.43 long-acting), quetiapine (1.59), amisulpride (1.43) |
| Under 1 kg | Iloperidone (0.78), asenapine (0.73), cariprazine (0.62), perphenazine (0.61), aripiprazole (0.41) |
| Similar to placebo | Flupentixol (0.10), aripiprazole long-acting (0.00), haloperidol (−0.01), lurasidone (−0.06), ziprasidone (−0.16) |
Two things worth noticing. The spread from top to bottom is enormous — this is not a class where all options are equivalent. And the older first-generation drugs are not uniformly better: chlorpromazine and pimozide sit at the top of the table, while haloperidol sits at the bottom.
A separate finding worth knowing: for most of these drugs the dose-response curve flattens at higher doses, but for aripiprazole, olanzapine and paliperidone it did not plateau in the available data — meaning dose may matter more for those.
Does Switching Fix It? Partly
The obvious response to antipsychotic-associated weight gain is to switch to a lower-risk drug. The evidence supports this less broadly than you might expect, and the honest answer has two halves.
Where it works. A systematic review of 59 studies found that switching to aripiprazole produced significant weight loss, and that switching to aripiprazole or ziprasidone was also associated with improvements in fasting glucose and triglycerides. Switching to olanzapine or clozapine went the other way.
Where it does not. A separate meta-analysis concluded that the rationale for switching antipsychotics specifically to reduce weight may be overrated, finding no reliable weight loss on switching to several drugs with favourable profiles. Switching to a metabolically friendlier drug does not automatically undo weight already gained.
The reconciliation: switching has the best evidence for specific drugs, chiefly aripiprazole and ziprasidone, rather than as a general tactic. And it carries its own risk — a drug that is controlling your symptoms is doing something that matters more than the number on the scale. That trade-off is your psychiatrist’s territory, not an article’s.
Why It Happens
The weight effects do not come from the dopamine blockade that produces the antipsychotic action. They come from what else these drugs bind to, which is why the differences between them are so large.
- Histamine H1 blockade — sedating and appetite-stimulating. The same mechanism behind mirtazapine’s appetite effect.
- Serotonin 5-HT2C blockade — removes a brake on appetite.
- Muscarinic blockade — contributes to metabolic effects alongside the above.
- Direct metabolic effects on glucose and lipids, which is why monitoring covers more than weight.
- Sedation reducing activity, particularly early in treatment.
Drugs that bind heavily at H1 and 5-HT2C — olanzapine and clozapine especially — are the ones at the top of the table. Those that do not are at the bottom.
Who Is Most Affected
The acute-trial network meta-analysis identified higher baseline weight and male sex as predictors of greater vulnerability to antipsychotic-induced metabolic change, and found differences by ethnicity in some markers. The authors noted this suggests an overlap with the ordinary risk factors for metabolic disease.
The clearest predictor remains treatment history: people who have not taken an antipsychotic before gain the most. That is an argument for the metabolic conversation happening at the start, not after two years.
What Is Actually Worth Doing
- Ask for baseline measurements. Weight, waist, blood pressure, fasting glucose and lipids before starting, then monitored. This is standard practice and worth confirming it is happening.
- Raise weight early, not late. Because gain is front-loaded and largest in first-time users, the first few months are when the conversation is most useful.
- Ask what the options are within the class. The spread between drugs is genuinely large, and effectiveness for your symptoms comes first — but there is often more than one drug that would work.
- Ask about added treatments. Metformin and other medications have been trialled specifically for antipsychotic-associated weight gain, and GLP-1 receptor agonists are an active area. Whether any is appropriate is a clinical decision.
- Never stop or skip doses. Weight gain is a manageable problem. Relapse is not, and stopping is the route to it.
Frequently Asked Questions
Across the evidence, olanzapine and clozapine consistently rank worst, with chlorpromazine, pimozide and zotepine also high in longer-term data. In one network meta-analysis of mid- to long-term trials, pimozide, chlorpromazine, clozapine, zotepine and olanzapine all produced more than 2 kg of weight gain in excess of placebo.
Aripiprazole, lurasidone and ziprasidone have the most favourable profiles, with cariprazine, asenapine and iloperidone also under 1 kg above placebo in longer-term data. Haloperidol, an older drug, also sits at the low end. Effectiveness for your symptoms comes first, and that is a decision for your psychiatrist.
Because duration and treatment history change the answer. Six-week acute trials produce much smaller figures than mid- to long-term trials, and people taking an antipsychotic for the first time gain considerably more than people switching between drugs. A meta-analysis of olanzapine in first-episode psychosis found a mean gain of around 7.5 kg, far above the acute-trial figures for the same drug.
Sometimes, and mainly for specific drugs. Reviews find weight loss on switching to aripiprazole or ziprasidone, along with improvements in glucose and triglycerides. But other analyses conclude that switching as a general strategy for weight is overrated, and switching carries its own risk to symptom control. It is a decision for your psychiatrist rather than a default.
Not through the dopamine blockade that produces the antipsychotic effect. The weight effects come mainly from blockade of histamine H1 and serotonin 5-HT2C receptors, which increase appetite, alongside muscarinic effects, direct effects on glucose and lipids, and sedation reducing activity. Drugs that bind heavily at H1 and 5-HT2C are the ones highest in the rankings.
No. Antipsychotics treat conditions where stopping carries severe consequences including relapse and hospitalisation. Weight gain is a manageable problem and relapse is not. Report the weight change to your psychiatrist, who can review the drug choice, the dose, monitoring, and whether an added treatment is appropriate.
Sources
- Burschinski A, Schneider-Thoma J, Chiocchia V, et al. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry, 2023.
- Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia: a systematic review and network meta-analysis. The Lancet Psychiatry, 2020.
- Correll CU, Højlund M, Graham C, et al. Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with olanzapine: a meta-analysis. 2023.
- Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? A systematic review and meta-analysis. Schizophrenia Bulletin, 2021.
- Bak M, Drukker M, Cortenraad S, et al. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch. PLOS ONE, 2021.
Related reading: Weight Gain Guide: causes, medications and when to see a doctor | Does mirtazapine cause weight gain? | Mental Health Guide
Written and fact-checked by the HealthCoachJP editorial team. No clinician has reviewed this article. It is general information about prescription medicines, not medical advice, not a dosing guide, and not a recommendation for or against any drug. Never stop, skip or change an antipsychotic without your psychiatrist — the risks of doing so are serious. If you are in crisis in the US, call or text 988. Last updated: August 2026. See our sourcing policy.
